• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LAI Yating,CHEN Caixin,ZHAO Zhongxiang,JIN Jing.Research progress of de novo synthesis reprogramming of fatty acids in lung cancer drug resistance[J].Journal Of Pharmaceutical Research,2025,44(3):265-269,274[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2073times   Download 790次 QR Code for this article
Scan with your phone!
脂肪酸从头合成重编程在肺癌耐药中的研究进展
赖雅婷1,2,陈采欣2,赵钟祥2,金晶1
Font:Larger+|Default|Smaller-
(1.中山大学药学院,广东 广州 510006;2.广州中医药大学中药学院,广东 广州 510006)
摘要:
肺癌是全世界最致命和最常见的癌症之一。酪氨酸激酶抑制剂(TKIs)可以靶向表皮生长因子受体(EGFR)来治疗肺癌,但患者在治疗后往往会出现耐药性。脂肪酸的从头合成代谢重编程被认为是导致肺癌耐药的重要原因,因此,靶向脂肪酸合成相关酶可能为开发抗肺癌耐药方案提供新的方向。本文综述了肺癌中脂肪酸从头合成与耐药性的关系,并探讨了重要酶和关键蛋白在其中的功能和作用,为开发肺癌耐药治疗新策略和潜在靶向药物提供参考。
关键词:  脂肪酸从头合成  脂质代谢  肺癌  耐药  表皮生长因子受体  靶向治疗
DOI:10.13506/j.cnki.jpr.2025.03.009
基金项目:国家自然科学基金项目(No.82274146)
Publication Date:March 25, 2025
Research progress of de novo synthesis reprogramming of fatty acids in lung cancer drug resistance
LAI Yating1,2,CHEN Caixin2,ZHAO Zhongxiang2,JIN Jing1
(1. School of Pharmacy, Sun Yat-sen University, Guangzhou 510006,China; 2. School of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China)
Abstract:
Lung cancer is one of the most lethal and common cancers in the world. Tyrosine kinase inhibitors (TKIs) can target epidermal growth factor receptor (EGFR) to treat lung cancer, but patients often develop drug resistance after treatment. De novo metabolic reprogramming of fatty acids is considered to be an important reason for drug resistance in lung cancer. Therefore, targeting fatty acid synthesis related enzymes may provide a new direction for the development of anti drug resistance schemes in lung cancer. This article reviews the relationship between de novo fatty acid synthesis and drug resistance in lung cancer, and discusses the functions and roles of important enzymes and key proteins in it, providing references for the development of new strategies and potential targeted drugs for the treatment of drug resistance in lung cancer.
Key words:  De novo synthesis of fatty acids  Lipid metabolism  Lung cancer  Drug resistance  EGFR  Targeted therapy
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.